<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277472</url>
  </required_header>
  <id_info>
    <org_study_id>CVAH631BUS04</org_study_id>
    <nct_id>NCT00277472</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension</brief_title>
  <official_title>A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination
      therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure control (systolic blood pressure &lt;140 and diastolic blood pressure &lt;90mmHg) after 4 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure control (systolic blood pressure &lt;140 and diastolic blood pressure &lt;90mmHg) after 2 weeks and 20 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure after 2 weeks and 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure after 2 weeks and 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure at 20 weeks compared to 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure at 20 weeks compared to 4 weeks</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>valsartan HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan/Hydrochlorothiazide</intervention_name>
    <description>160/12.5 mg taken once daily orally</description>
    <arm_group_label>valsartan HCTZ</arm_group_label>
    <other_name>Co-Diovan, Diovan HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCTZ</intervention_name>
    <description>25 mg taken once daily orally</description>
    <arm_group_label>HCTZ</arm_group_label>
    <other_name>hydrochlorothiazice, water pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age and older

          -  Diagnosed as having hypertension (mean seated systolic blood pressure ≥ 150 mm Hg but
             &lt; 180 mm Hg and mean seated diastolic blood pressure ≥ 95 mm Hg and &lt;110 mm Hg

        Exclusion Criteria:

          -  - Patients with sever hypertension: Systolic ≥ 180 mm Hg or Diastolic ≥ 110 mm Hg

          -  Diabetes with fasting glucose &gt; 126 mg/dl or on existing anti-diabetic medication

          -  History of stroke, transient ischemic attack, or myocardial infarction within the last
             6 months, or diagnosed with congestive heart failure.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis 862-778-8300 Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2006</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Novartis Pharma</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High blood pressure</keyword>
  <keyword>diuretics</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

